L & S Advisors’s Editas Medicine EDIT Stock Holding History

L & S Advisors’s Portfolio EDIT Stock Details EDIT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-4,000	Closed	-$280K	–	359
2020 Q4	$280K	Buy	+4,000	New	+$164K	0.03%	285

Other funds holding EDIT

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

L & S Advisors's EDIT Position: Q1 2021 in Review

L & S Advisors sold out of Editas Medicine (EDIT) in Q1 2021, closing a stake of 4,000 shares — an estimated $280K sold.

L & S Advisors first reported a position in EDIT in Q4 2020 and held it in 1 quarter. The position peaked at $280K in Q4 2020. 312 funds tracked by Wall St. Rank hold EDIT as of Q1 2021.

L & S Advisors reported no remaining Editas Medicine position as of Q1 2021 after selling out during the quarter.
L & S Advisors sold 4,000 Editas Medicine shares in Q1 2021, an estimated $280K.
L & S Advisors first reported a position in Editas Medicine in Q4 2020 and held it in 1 quarter.
L & S Advisors's Editas Medicine position peaked at $280K in Q4 2020.
312 funds tracked by Wall St. Rank held Editas Medicine as of Q1 2021.

Based on L & S Advisors's 13F filing for Q1 2021, filed 10 May 2021.